[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"CND Life Sciences\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":93},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,71],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100625885","analysis-of-cutaneous-phosphorylated-alpha-synuclein-to-identify-patients-at-risk-of-progressing-from-essential-tremor-to-parkinsons-disease-100625885",false,"NCT07428447","Analysis of Cutaneous Phosphorylated Alpha-Synuclein to Identify Patients at Risk of Progressing From Essential Tremor to Parkinson's Disease","Syn-T","Inclusion Criteria:\n\n* Age 50-85 years old\n* Diagnosis of ET as defined by the 2018 MDS Task force paper \"1) isolated tremor syndrome of bilateral upper limb action tremor 2) at least 3 years' duration 3) with or without tremor in other locations (e.g., head, voice, or lower limbs) 4) absence of other neurological signs, such as dystonia, ataxia, or parkinsonism.\" OR\n* Diagnosis of ET-Plus as stated by the 2018 MDS Task force paper, \"Tremor with the characteristics of ET and additional neurological signs of uncertain significance such as impaired tandem gait, questionable dystonic posturing, memory impairment, or other mild neurologic signs of unknown significance that do not suffice to make an additional syndrome classification or diagnosis. ET with tremor at rest should be classified here.\"\n* Willing to participate in all study procedures\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* Under age 50, Over age 85\n* Clinical evidence of severe peripheral vascular disease\n* Clinically active coronary artery or cerebrovascular disease\n* Participant is currently on anticoagulant or dual anti-platelet therapy\n* Alcoholism\n* Allergic reaction to local anesthesia\n* History of or increased risk for impaired wound healing, scarring, or keloid formation\n* Diagnosis of ET or ET-Plus that is clinically determined to likely be secondary to brain injury or vascular compromise\n* History of other neurodegenerative disorder or evidence of neurological co-pathology\n* Abnormal DaTscan\n* Participant is currently receiving treatment with carbidopa-levodopa for PD\n* Isolated focal tremors (head, voice)\n* Task-specific tremor (e.g., primary writing tremor)\n* Position-specific tremors that does not otherwise meet clinical diagnostic criteria for ET\n* Sudden onset and step-wise deterioration","ALL","50 Years","85 Years",{"count":20,"type":21},300,"ESTIMATED","OBSERVATIONAL","Background and Rationale Essential tremor (ET) affects over 6 million Americans and approximately 5% of adults over age 60. Patients with ET have a 10-20 times higher risk of developing Parkinson's disease (PD) compared to age-matched populations, with approximately 1% converting to PD annually. Post-mortem studies reveal Lewy body pathology in some ET patients, suggesting a subset may have prodromal PD. Current diagnostic tools (DaTscan, SYNTap) are either insufficiently sensitive for early disease, too expensive, or too invasive for routine screening. The Syn-One Test offers a minimally invasive approach to detect phosphorylated α-synuclein (P-SYN) pathology in skin biopsies.\n\nPrimary Objectives\n\n1. Identify which ET patients have P-SYN pathology indicative of prodromal PD\n2. Predict which patients are most likely to phenoconvert to PD",[25,26,27],"Essential Tremor, Movement Disorders","Essential Tremor","Essential Tremor-plus",[29,30],"skin biopsy","Syn-One","RECRUITING","2026-07-01",{"date":34,"type":35},"2026-07-02","ACTUAL",{"date":37,"type":35},"2026-02-18",{"date":39,"type":21},"2029-02",{"name":41,"class":42},"CND Life Sciences","OTHER",2,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},"100609628","colonic-tissue-biopsy-detection-of-phosphorylated-alpha-synuclein-for-parkinsons-diagnosis-or-rem-sleep-behavior-disorder-100609628","NCT07217054","Colonic Tissue Biopsy Detection of Phosphorylated Alpha-synuclein for Parkinson's Diagnosis or REM Sleep Behavior Disorder","Detection of Phosphorylated Alpha-Synuclein in Colonic Tissue Biopsy During Routine Colonoscopy","Syn-G","Inclusion Criteria:\n\n1. Relatively healthy men and women ≥40-99 years of age\n2. Patients with a diagnosis of\n\n   1. Clinically confirmed PD or\n   2. Clinically confirmed RBD with no diagnosis of PD, DLB or MSA\n3. Patients must have agreed to undergo a routine colonoscopy as part of their screening or surveillance for colon cancer or for diagnostic purposes for the exclusion of other GI diseases\n\nExclusion Criteria:\n\n1. Use of anticoagulants (Plavix or aspirin alone is allowed)\n2. Under active treatment for colon cancer; 30-day post anti-cancer treatment allowed\n3. Current, ongoing gastrointestinal illness\n4. Recent intrabdominal surgery\n5. Pregnant or planning to become pregnant before the scheduled colonoscopy\n6. Significant cognitive impairment, as determined by study investigators","40 Years","99 Years",{"count":55,"type":21},40,"The goal of this observational study is to learn whether tissue samples taken from the colon during routine colonoscopy can detect signs of Parkinson's disease or REM Sleep Behavior Disorder (RBD). The main question it aims to answer is:\n\nCan doctors find a protein called alpha-synuclein in colon tissue samples from people with Parkinson's disease and RBD?\n\nCurrently, Parkinson's disease is diagnosed by observing symptoms like tremors and movement problems and RBD by loss of muscle atonia during REM sleep, but by then the disease has already progressed significantly. Earlier detection could help doctors start treatment sooner.",[58,59,60,61],"PARKINSON DISEASE (Disorder)","Parkinson","Parkinson s Disease","Parkinson Disease","2026-02-09",{"date":64,"type":35},"2026-02-11",{"date":66,"type":35},"2025-11-04",{"date":68,"type":21},"2029-10",{"name":41,"class":42},1,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":50,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":53,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":87,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":70},"100608676","colonoscopic-detection-of-phosphorylated-alpha-synuclein-for-parkinsons-diagnosis-100608676","NCT07204652","Colonoscopic Detection of Phosphorylated Alpha-synuclein for Parkinson's Diagnosis","Detection of Phosphorylated Alpha-synuclein Through Routine Colonoscopy to Diagnose Parkinson's Disease and Related Disorders","Inclusion Criteria:\n\n* Adults 40 to 99 years of age\n* Patients with a confirmed clinical diagnosis of Parkinson's disease by UKPDS Brain Bank Criteria\n* Patients who have agreed to undergo a routine colonoscopy as part of their surveillance for colon cancer or exclusion of other gastrointestinal diseases\n\nExclusion Criteria:\n\n* Use of anticoagulants (Plavix 75 mg or aspirin up to 325 mg alone is allowed)\n* History of colon cancer\n* Recent gastrointestinal illness or surgical procedures\n* Pregnant or planning to become pregnant before the scheduled colonoscopy\n* Significant cognitive impairment, as determined by study investigators\n* Decisionally impaired adults who cannot express understanding that this study is voluntary and for research purposes",{"count":79,"type":21},20,"The goal of this observational study is to learn whether tissue samples taken from the colon during routine colonoscopy can detect signs of Parkinson's disease. The main question it aims to answer is:\n\nCan doctors find a protein called alpha-synuclein in colon tissue samples from people with Parkinson's disease?\n\nCurrently, Parkinson's disease is diagnosed by observing symptoms like tremors and movement problems, but by then the disease has already progressed significantly. Earlier detection could help doctors start treatment sooner.",[58,59,82,61],"Parkinson's Disease and Parkinsonism",[59,84,85,86],"Parkinson's Disease","Parkinson disease","Parkinson Disease (Disorder)",{"date":64,"type":35},{"date":89,"type":35},"2025-09-03",{"date":91,"type":21},"2029-09",{"name":41,"class":42},""]